Market Overview

Emmaus Life Sciences Strengthens its Finance & Operations Leadership to Support Commercialization of Endari™


Adds Kurt Kruger as CFO; Daniel Frey as Controller

Emmaus Life Sciences, Inc. (Emmaus), having initiated the commercial
roll-out of Endari™ (L-glutamine oral powder), its prescription drug for
sickle cell disease, has strengthened its operations by appointing Mr.
Kurt Kruger as Chief Financial Officer and Mr. Daniel Frey as
Controller. Mr. Kruger succeeds Willis C. Lee, who will continue as the
company's Chief Operating Officer and Vice Chairman of Emmaus. Endari™
was approved by the FDA in July 2017 to reduce the acute complications
of sickle cell disease in adult and pediatric patients 5 years and older.

"We're excited to have both Kruger and Frey join our management team as
we continue the transition to a commercial-stage company," said Yutaka
Niihara, MD, MPH, Chairman and CEO of Emmaus Life Sciences. "With
approval by the FDA last year to market Endari™, we have dramatically
increased our sales and marketing activities. Kruger's and Frey's
financial and operational expertise and leadership will further advance
these efforts."

Mr. Kurt Kruger, Chief Financial Officer

Until recently, Mr. Kruger headed up the life sciences investment
banking group for WR Hambrecht + Co. With a 30-plus year career in the
life sciences industry, his experience ranges from product design as a
biomedical engineer to raising capital for, and following,
publicly-traded medical products companies.

Early in his career, he served as a marketing manager for CPI/Guidant,
now Boston Scientific, a large pacemaker company, where he developed the
launch plans for the first-ever implantable defibrillator. Mr. Kruger
then went on to Wall Street where he continued to work in life sciences
as a high-profile equities research analyst for two well-regarded
investment banks, Hambrecht & Quist and Montgomery Securities (Banc of
America Securities), firms that played significant roles in funding many
of the notable biotechnology and medical products companies such as
Genentech, Amgen, Ventritex, Cytyc and Kyphon.

Mr. Kruger received an Sc.B. degree in Biomedical Engineering from Brown
University, a Master's degree in Bioengineering from the University of
Michigan, and a business degree (S.M.) from the Sloan School at the
Massachusetts Institute of Technology (MIT). He also completed the
premedical post-baccalaureate program at Columbia University.

Mr. Daniel Frey, Controller

Mr. Frey has more than 20 years of financial experience, both
domestically and internationally, in privately held and publicly-traded
companies, as well as government organizations. He possesses extensive
experience reporting financial results to board of directors, investors,
executive and audit committees under United States GAAP, as well as, SEC
reporting guidelines.

Mr. Frey began his career in the Los Angeles offices of
PriceWaterhouseCoopers. Since then he has held senior financial
management roles at Occidental Petroleum Corporation, Digicel, a
multinational Jamaica-based cellular service provider, United States
Agency for International Development, TPx Communications, a
communications and network provider, and as a financial consultant at
Toyota Financial Services and Willis Tower Watson, a global
multinational risk management company.

Mr. Frey is a Certified Public Accountant (inactive) in California and
received a B.S. in Business Administration from California State
University, Northridge.

Important Safety Information

The most common adverse reactions (incidence>10 percent) in clinical
studies were constipation, nausea, headache, abdominal pain, cough, pain
in extremities, back pain and chest pain.

Adverse reactions leading to the treatment discontinuation included one
case each of hypersplenism, abdominal pain, dyspepsia, burning sensation
and hot flash.

The safety and efficacy of Endari™ in pediatric patients with sickle
cell disease younger than five years of age has not been established.

For more information, please see the full Prescribing Information of
Endari™ at

About Emmaus Life Sciences

Emmaus Life Sciences, Inc. is engaged in the discovery, development and
commercialization of innovative treatments and therapies for rare
diseases. The company's research on sickle cell disease was initiated by
Yutaka Niihara, MD, MPH, Chairman and CEO of Emmaus, at the Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical Center. For more
information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
regarding the commercialization of Endari™ and related matters. Such
forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, including factors that could cause
actual outcomes and results to differ materially from current
expectations. These risks and uncertainties are described in reports
filed by Emmaus Life Sciences, Inc. with the U.S. Securities and
Exchange Commission, including its Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q. Emmaus is providing this information as
of the date of this press release and does not undertake any obligation
to update any forward-looking statements as a result of new information,
future events or otherwise.

View Comments and Join the Discussion!